Literature DB >> 31048350

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Bart G J Dekkers1, Mathieu S Bolhuis2, Lies Ter Beek3,4,5, Wiel C M de Lange3,4, Tjip S van der Werf3,6, Jan-Willem C Alffenaar2,7, Onno W Akkerman3,4.   

Abstract

Entities:  

Year:  2019        PMID: 31048350     DOI: 10.1183/13993003.00373-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Clinical standards for drug-susceptible pulmonary TB.

Authors:  O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-07-01       Impact factor: 3.427

2.  Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients.

Authors:  Vanessa B Vogensen; Mathieu S Bolhuis; Marieke G G Sturkenboom; Tjip S van der Werf; Wiel C M de Lange; Richard M Anthony; Dick van Soolingen; Jan-Willem Alffenaar; Huib A M Kerstjens; Onno W Akkerman
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

3.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

4.  Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.

Authors:  Hwi-Yeol Yun; Vincent Chang; Kendra K Radtke; Qianwen Wang; Natasha Strydom; Min Jung Chang; Radojka M Savic
Journal:  Open Forum Infect Dis       Date:  2021-12-29       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.